Halsey Associates Boosted Its Regeneron Pharmaceuticals (REGN) Stake by $2.89 Million; Stock Value Rose; Lattice Semiconductor (LSCC) Market Valuation Rose While Alpine Associates Management Has Lifted Its Holding

February 17, 2018 - By Lawrence Diaz

Halsey Associates Inc increased its stake in Regeneron Pharmaceuticals (REGN) by 74.89% based on its latest 2017Q3 regulatory filing with the SEC. Halsey Associates Inc bought 6,458 shares as the company’s stock rose 21.24% with the market. The institutional investor held 15,081 shares of the health care company at the end of 2017Q3, valued at $6.74M, up from 8,623 at the end of the previous reported quarter. Halsey Associates Inc who had been investing in Regeneron Pharmaceuticals for a number of months, seems to be bullish on the $35.71 billion market cap company. The stock decreased 0.31% or $1.03 during the last trading session, reaching $332.15. About 1.18 million shares traded or 23.56% up from the average. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has risen 17.40% since February 17, 2017 and is uptrending. It has outperformed by 0.70% the S&P500.

Robert Emil Zoellner increased its stake in Lattice Semiconductor Corp (LSCC) by 11.79% based on its latest 2017Q3 regulatory filing with the SEC. Alpine Associates Management Inc bought 318,248 shares as the company’s stock rose 1.45% with the market. The hedge fund run by Robert Emil Zoellner held 3.02 million shares of the semiconductors company at the end of 2017Q3, valued at $15.72 million, up from 2.70M at the end of the previous reported quarter. Alpine Associates Management Inc who had been investing in Lattice Semiconductor Corp for a number of months, seems to be bullish on the $679.75 million market cap company. The stock increased 0.92% or $0.05 during the last trading session, reaching $5.51. About 1.12M shares traded. Lattice Semiconductor Corporation (NASDAQ:LSCC) has risen 35.73% since February 17, 2017 and is uptrending. It has outperformed by 19.03% the S&P500.

Since August 16, 2017, it had 2 buys, and 5 insider sales for $112.50 million activity. $80.03 million worth of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares were bought by Sanofi. On Friday, September 29 BAKER CHARLES A sold $900,000 worth of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) or 2,000 shares. BROWN MICHAEL S sold $712,500 worth of stock or 1,500 shares. Another trade for 56,213 shares valued at $26.67M was made by VAGELOS P ROY on Monday, August 21.

Halsey Associates Inc, which manages about $849.92M and $507.35M US Long portfolio, decreased its stake in Berkshire Hathaway B (BRKB) by 2,270 shares to 105,950 shares, valued at $19.42 million in 2017Q3, according to the filing. It also reduced its holding in Apple (NASDAQ:AAPL) by 5,878 shares in the quarter, leaving it with 156,260 shares, and cut its stake in Coca Cola (NYSE:KO).

Among 33 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 14 have Buy rating, 1 Sell and 18 Hold. Therefore 42% are positive. Regeneron Pharmaceuticals Inc. had 117 analyst reports since July 28, 2015 according to SRatingsIntel. UBS upgraded the stock to “Buy” rating in Monday, September 7 report. As per Thursday, November 9, the company rating was maintained by Morgan Stanley. Jefferies maintained the stock with “Hold” rating in Thursday, October 5 report. Morgan Stanley maintained it with “Equal-Weight” rating and $415 target in Friday, February 9 report. The firm has “Neutral” rating given on Wednesday, January 20 by Credit Suisse. Chardan Capital Markets upgraded the shares of REGN in report on Tuesday, February 16 to “Neutral” rating. The stock has “Buy” rating by RBC Capital Markets on Monday, August 31. The company was maintained on Sunday, February 11 by Piper Jaffray. The stock of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) earned “Market Perform” rating by Wells Fargo on Wednesday, April 20. As per Thursday, August 3, the company rating was maintained by J.P. Morgan.

Investors sentiment decreased to 1.17 in Q3 2017. Its down 0.21, from 1.38 in 2017Q2. It dropped, as 56 investors sold REGN shares while 165 reduced holdings. 71 funds opened positions while 187 raised stakes. 73.70 million shares or 3.04% more from 71.53 million shares in 2017Q2 were reported. Fukoku Mutual Life Ins has 390 shares. Valley Advisers Inc has 0.05% invested in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Minnesota-based Ameriprise Financial Inc has invested 0.05% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Adage Capital Prns Grp Limited Liability Corp owns 11,910 shares for 0.01% of their portfolio. Livforsakringsbolaget Skandia Omsesidigt stated it has 0.06% in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Roundview Capital Lc holds 0.12% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for 852 shares. Neuberger Berman Ltd Limited Liability Company holds 291,878 shares or 0.16% of its portfolio. Swiss Comml Bank holds 288,500 shares. Prentiss Smith & Co Inc holds 0.25% or 931 shares. 58,270 are owned by Eaton Vance Management. Bnp Paribas Arbitrage has 0.52% invested in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Sands Capital Lc holds 2.64M shares or 3.54% of its portfolio. Brown Brothers Harriman & stated it has 0% of its portfolio in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). Conning invested in 2,110 shares or 0.03% of the stock. Fagan Assocs holds 3,318 shares.

Investors sentiment decreased to 1 in 2017 Q3. Its down 0.51, from 1.51 in 2017Q2. It fall, as 14 investors sold LSCC shares while 44 reduced holdings. 23 funds opened positions while 35 raised stakes. 98.38 million shares or 0.41% more from 97.99 million shares in 2017Q2 were reported. Natixis has invested 0% of its portfolio in Lattice Semiconductor Corporation (NASDAQ:LSCC). The New York-based Jane Street Group Limited Co has invested 0% in Lattice Semiconductor Corporation (NASDAQ:LSCC). Geode Cap Ltd Limited Liability Company has invested 0% in Lattice Semiconductor Corporation (NASDAQ:LSCC). Aperio Gru Ltd Liability accumulated 17,607 shares. California State Teachers Retirement invested in 0% or 196,250 shares. Great West Life Assurance Can holds 0.01% or 846,424 shares in its portfolio. Legal General Gp Public Ltd holds 43,682 shares. Cornerstone Cap Mngmt Limited Co has 19,497 shares. Invesco Limited has 0% invested in Lattice Semiconductor Corporation (NASDAQ:LSCC). Wolverine Asset Management Ltd Liability Com invested 0% of its portfolio in Lattice Semiconductor Corporation (NASDAQ:LSCC). International Group Inc invested in 82,332 shares or 0% of the stock. Commercial Bank Of Montreal Can holds 199 shares or 0% of its portfolio. 38,940 are held by Public Employees Retirement Association Of Colorado. Grantham Mayo Van Otterloo Company Ltd Liability Company, Massachusetts-based fund reported 2.20M shares. Moreover, Css Llc Il has 0.01% invested in Lattice Semiconductor Corporation (NASDAQ:LSCC) for 31,400 shares.

Among 5 analysts covering Lattice Semiconductor (NASDAQ:LSCC), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Lattice Semiconductor had 16 analyst reports since August 4, 2015 according to SRatingsIntel. The stock has “Buy” rating by Jefferies on Wednesday, August 10. The stock of Lattice Semiconductor Corporation (NASDAQ:LSCC) earned “Neutral” rating by Robert W. Baird on Thursday, November 3. The firm earned “Hold” rating on Tuesday, September 19 by Robert W. Baird. On Tuesday, August 4 the stock rating was downgraded by Zacks to “Hold”. The company was maintained on Monday, September 11 by Jefferies. The rating was maintained by FBR Capital with “Outperform” on Thursday, February 18. On Tuesday, September 20 the stock rating was initiated by Susquehanna with “Positive”. The stock has “Hold” rating by Craig Hallum on Thursday, April 14. The stock of Lattice Semiconductor Corporation (NASDAQ:LSCC) earned “Hold” rating by Jefferies on Thursday, September 14. Jefferies maintained the stock with “Hold” rating in Monday, July 10 report.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>